Recent developments for optimal end-points in rheumatoid arthritis clinical studies

Molenaar, E. T. M., Boers, M., Brooks, P. M., Simon, L., Strand, V. and Tugwell, P. (2000) Recent developments for optimal end-points in rheumatoid arthritis clinical studies. Disease Management & Health Outcomes, 8 2: 87-97. doi:10.2165/00115677-200008020-00004


Author Molenaar, E. T. M.
Boers, M.
Brooks, P. M.
Simon, L.
Strand, V.
Tugwell, P.
Title Recent developments for optimal end-points in rheumatoid arthritis clinical studies
Journal name Disease Management & Health Outcomes   Check publisher's open access policy
ISSN 1173-8790
Publication date 2000
Sub-type Critical review of research, literature review, critical commentary
DOI 10.2165/00115677-200008020-00004
Volume 8
Issue 2
Start page 87
End page 97
Total pages 11
Place of publication New Zealand
Publisher ADIS International
Collection year 2000
Language eng
Subject C1
321028 Rheumatology and Arthritis
730114 Skeletal system and disorders (incl. arthritis)
1103 Clinical Sciences
1117 Public Health and Health Services
Abstract Clinical studies in patients with rheumatoid arthritis (RA) provide valuable information on the course and outcome of the disease whereas clinical trials provide information on optimal treatment for patients. This paper discusses measurement concepts and most frequently used measures in RA. To optimise the information that can be obtained from clinical studies, uniform measures are essential, Therefore, the international rheumatology community has made an effort to propose uniform end-points for clinical studies in RA, Measurement in RA is traditionally divided into the measurement of 'the process' and measurement of 'outcome'. Current measures in use include: (i) disease activity measures - global assessments, symptoms (e.g. morning stiffness), health status! physical function, physical signs (e.g. joint counts) and laboratory assessments; and (ii) measures of damage - radiography of affected joints and physical function. Several Outcome Measures in Rheumatology (OMERACT) conferences have resulted in a core set of end-points to be used in RA clinical trials, which are supported by the World Health Organization and International League of Associations for Rheumatology (WHO/ILAR). In addition, the OMERACT conferences focused on minimum important differences for patients and in trials, resulting in recommendations for improvement criteria. Improvement criteria were further developed and validated by both the American College of Rheumatology (ACR) and European League Against Rheumatology (EULAR). The ACR criteria use the WHO/ILAR core set of end-points to define minimum improvement in each of the measures. The EULAR criteria define improvement using the Disease Activity Score.
Keyword Health Care Sciences & Services
College-of-rheumatology
World-health-organization
Modifying Antirheumatic Drugs
Administered Joint Counts
Disease-activity Score
Outcome Measures
Motion Scale
Improvement Criteria
Functional Disability
Omeract Conference
Q-Index Code C1

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collection: School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 3 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Tue, 10 Jun 2008, 12:55:22 EST